Perhexiline maleate, a new anti-anginal drug, evaluated by "modified double blind double cross over study".
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000787:Angina Pectoris / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002493:Central Nervous System Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004562:Electrocardiography; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010480:Perhexiline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005082:Physical Exertion; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos; D013610:Tachycardia / Q000517:prevention & control; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010880:Piperidines; D010919:Placebos; D014665:Vasodilator Agents; D000410:Alanine Transaminase; D010480:Perhexiline